Moxifloxacine Fresenius Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. Inhibiting these targets prevents bacterial DNA from unwinding and separating, leading to cell death and effective eradication of susceptible Gram‑positive and Gram‑negative organisms.

The specific dose and infusion rate are determined by the prescribing clinician based on the infection type, severity, patient weight, renal function and local guidelines. Healthcare professionals should follow the product label and institutional protocols when prescribing.

Safety data in pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians must evaluate each case individually and discuss alternatives when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Moxifloxacin offers a broader spectrum against both Gram‑positive and Gram‑negative bacteria and has enhanced activity against atypical pathogens compared with older fluoroquinolones. It also has a lower propensity for drug‑induced photosensitivity, but shares class‑wide risks such as tendon injury and QT prolongation.

The product should be stored at 2‑8 °C, protected from light, and kept in its original container. It must not be frozen or shaken, and any solution that has been left at room temperature for longer than the recommended time should be discarded.

Moxifloxacine Fresenius Kabi is supplied as an intravenous solution. It is administered by slow infusion into a peripheral or central vein, following aseptic technique. The infusion rate and duration are set by the prescriber according to the clinical protocol.

Serious risks include tendon rupture, especially in the Achilles tendon, QT interval prolongation leading to arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and rare cases of hepatic failure. Prompt recognition and discontinuation are essential if these events occur.

Patients with a known hypersensitivity to moxifloxacin, other fluoroquinolones, or any component of the formulation should avoid this drug. It is also contraindicated in individuals with a history of tendon disorders related to fluoroquinolone use, and caution is advised for those with significant QT prolongation or uncontrolled cardiac arrhythmias.